247 related articles for article (PubMed ID: 30602977)
1. Prevalence of rifampicin resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos Nigeria.
Adejumo OA; Olusola-Faleye B; Adepoju V; Bowale A; Adesola S; Falana A; Owuna H; Otemuyiwa K; Oladega S; Adegboye O
Afr Health Sci; 2018 Sep; 18(3):472-478. PubMed ID: 30602977
[TBL] [Abstract][Full Text] [Related]
2. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
[TBL] [Abstract][Full Text] [Related]
3. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
Chatla C; Jaju J; Achanta S; Samyuktha R; Chakramahanti S; Purad C; Chepuri R; Nair SA; Parmar M
Indian J Tuberc; 2018 Jul; 65(3):218-224. PubMed ID: 29933863
[TBL] [Abstract][Full Text] [Related]
4. Trends of Mycobacterium tuberculosis and Rifampicin resistance in Northwest Ethiopia: Xpert® MTB/RIF assay results from 2015 to 2021.
Biset S; Teferi M; Alamirew H; Birhanu B; Dessie A; Aschale A; Haymanot A; Dejenie S; Gebremedhin T; Abebe W; Adane G
BMC Infect Dis; 2024 Feb; 24(1):238. PubMed ID: 38389060
[TBL] [Abstract][Full Text] [Related]
5. Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.
Wasihun AG; Dejene TA; Hailu GG
PLoS One; 2020; 15(11):e0240361. PubMed ID: 33147218
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Mycobacterium Tuberculosis Positive Patients Screened for Drug-Resistant Tuberculosis at a Tertiary Health Facility in Lagos, Nigeria.
Kuyinu YA; Odugbemi BA; Salisu-Olatunji SO; Adepoju FO; Odusanya OO
J Natl Med Assoc; 2018 Feb; 110(1):88-91. PubMed ID: 29510850
[TBL] [Abstract][Full Text] [Related]
7. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
Steingart KR; Sohn H; Schiller I; Kloda LA; Boehme CC; Pai M; Dendukuri N
Cochrane Database Syst Rev; 2013 Jan; (1):CD009593. PubMed ID: 23440842
[TBL] [Abstract][Full Text] [Related]
8. Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study.
Mulu W; Abera B; Yimer M; Hailu T; Ayele H; Abate D
BMC Res Notes; 2017 Jan; 10(1):8. PubMed ID: 28057041
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
[TBL] [Abstract][Full Text] [Related]
10. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
Iem V; Dean A; Zignol M; Vongvichit P; Inthavong D; Siphanthong S; Sorsavanh T; Kim SJ; Shin S; Sébert J; Chittamany P
Trop Med Int Health; 2019 Apr; 24(4):421-431. PubMed ID: 30663180
[TBL] [Abstract][Full Text] [Related]
11. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment attrition and treatment initiation delay among rifampicin-resistant tuberculosis patients in Lagos, Nigeria: a retrospective cohort study.
Adejumo OA; Daniel O; Adepoju VA; Onoh MO; Sokoya OD; Abdur-Razzaq H; Moronfolu O; Oyadotun OM; Olusola-Faleye B
Trans R Soc Trop Med Hyg; 2022 Dec; 116(12):1154-1161. PubMed ID: 35710310
[TBL] [Abstract][Full Text] [Related]
14. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
[TBL] [Abstract][Full Text] [Related]
15. Continuous surveillance of drug-resistant TB burden in Rwanda: a retrospective cross-sectional study.
Habimana-Mucyo Y; Dushime A; Migambi P; Habiyambere I; Semuto Ngabonziza JC; Decroo T
Int Health; 2023 Jul; 15(4):357-364. PubMed ID: 35653710
[TBL] [Abstract][Full Text] [Related]
16. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
[TBL] [Abstract][Full Text] [Related]
17. Performance of the Xpert MTB/RIF assay in the diagnosis of tuberculosis in formalin-fixed, paraffin-embedded tissues.
Polepole P; Kabwe M; Kasonde M; Tembo J; Shibemba A; O'Grady J; Kapata N; Zumla A; Bates M
Int J Mycobacteriol; 2017; 6(1):87-93. PubMed ID: 28317811
[TBL] [Abstract][Full Text] [Related]
18. Rifampicin resistance patterns and dynamics of tuberculosis and drug-resistant tuberculosis in Enugu, South Eastern Nigeria.
Ugwu KO; Onah IS; Mbah GC; Ezeonu IM
J Infect Dev Ctries; 2020 Sep; 14(9):1011-1018. PubMed ID: 33031090
[TBL] [Abstract][Full Text] [Related]
19. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
[TBL] [Abstract][Full Text] [Related]
20. Age and sex distribution of Mycobacterium tuberculosis infection and rifampicin resistance in Myanmar as detected by Xpert MTB/RIF.
Seifert M; Aung HT; Besler N; Harris V; Mar TT; Colman RE; Rodwell TC; Aung ST
BMC Infect Dis; 2021 Aug; 21(1):781. PubMed ID: 34372793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
